These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 18389263)

  • 1. Clinical, neuropathological and genotypic variability in SNCA A53T familial Parkinson's disease. Variability in familial Parkinson's disease.
    Markopoulou K; Dickson DW; McComb RD; Wszolek ZK; Katechalidou L; Avery L; Stansbury MS; Chase BA
    Acta Neuropathol; 2008 Jul; 116(1):25-35. PubMed ID: 18389263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathological findings in a patient with alpha-synuclein p.A53T and familial Parkinson's disease.
    Nishioka K; Hashizume Y; Takanashi M; Daida K; Li Y; Yoshino H; Tambasco N; Prontera P; Hattori Y; Ueda A; Watanabe H; Hattori N
    Parkinsonism Relat Disord; 2020 Dec; 81():183-187. PubMed ID: 33171430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct clinical and neuropathological features of G51D SNCA mutation cases compared with SNCA duplication and H50Q mutation.
    Kiely AP; Ling H; Asi YT; Kara E; Proukakis C; Schapira AH; Morris HR; Roberts HC; Lubbe S; Limousin P; Lewis PA; Lees AJ; Quinn N; Hardy J; Love S; Revesz T; Houlden H; Holton JL
    Mol Neurodegener; 2015 Aug; 10():41. PubMed ID: 26306801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. α-Synuclein BAC transgenic mice exhibit RBD-like behaviour and hyposmia: a prodromal Parkinson's disease model.
    Taguchi T; Ikuno M; Hondo M; Parajuli LK; Taguchi K; Ueda J; Sawamura M; Okuda S; Nakanishi E; Hara J; Uemura N; Hatanaka Y; Ayaki T; Matsuzawa S; Tanaka M; El-Agnaf OMA; Koike M; Yanagisawa M; Uemura MT; Yamakado H; Takahashi R
    Brain; 2020 Jan; 143(1):249-265. PubMed ID: 31816026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. α-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy?
    Kiely AP; Asi YT; Kara E; Limousin P; Ling H; Lewis P; Proukakis C; Quinn N; Lees AJ; Hardy J; Revesz T; Houlden H; Holton JL
    Acta Neuropathol; 2013 May; 125(5):753-69. PubMed ID: 23404372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inclusion body formation and neurodegeneration are parkin independent in a mouse model of alpha-synucleinopathy.
    von Coelln R; Thomas B; Andrabi SA; Lim KL; Savitt JM; Saffary R; Stirling W; Bruno K; Hess EJ; Lee MK; Dawson VL; Dawson TM
    J Neurosci; 2006 Apr; 26(14):3685-96. PubMed ID: 16597723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pathology of familial Parkinson's disease].
    Wakabayashi K; Takahashi H
    Brain Nerve; 2007 Aug; 59(8):851-64. PubMed ID: 17713121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The regulatory role of α-synuclein and parkin in neuronal cell apoptosis; possible implications for the pathogenesis of Parkinson's disease.
    Yasuda T; Mochizuki H
    Apoptosis; 2010 Nov; 15(11):1312-21. PubMed ID: 20221696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional study.
    Wilson H; Dervenoulas G; Pagano G; Koros C; Yousaf T; Picillo M; Polychronis S; Simitsi A; Giordano B; Chappell Z; Corcoran B; Stamelou M; Gunn RN; Pellecchia MT; Rabiner EA; Barone P; Stefanis L; Politis M
    Lancet Neurol; 2019 Aug; 18(8):748-759. PubMed ID: 31229470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel α-synuclein mutation A53E associated with atypical multiple system atrophy and Parkinson's disease-type pathology.
    Pasanen P; Myllykangas L; Siitonen M; Raunio A; Kaakkola S; Lyytinen J; Tienari PJ; Pöyhönen M; Paetau A
    Neurobiol Aging; 2014 Sep; 35(9):2180.e1-5. PubMed ID: 24746362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parkinson's disease with Lewy bodies associated with a heterozygous PARKIN dosage mutation.
    Sharp ME; Marder KS; Côté L; Clark LN; Nichols WC; Vonsattel JP; Alcalay RN
    Mov Disord; 2014 Apr; 29(4):566-8. PubMed ID: 24375549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. α-synuclein expression from a single copy transgene increases sensitivity to stress and accelerates neuronal loss in genetic models of Parkinson's disease.
    Cooper JF; Spielbauer KK; Senchuk MM; Nadarajan S; Colaiácovo MP; Van Raamsdonk JM
    Exp Neurol; 2018 Dec; 310():58-69. PubMed ID: 30194957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic assessment of familial and early-onset Parkinson's disease in a Greek population.
    Bozi M; Papadimitriou D; Antonellou R; Moraitou M; Maniati M; Vassilatis DK; Papageorgiou SG; Leonardos A; Tagaris G; Malamis G; Theofilopoulos D; Kamakari S; Stamboulis E; Hadjigeorgiou GM; Athanassiadou A; Michelakakis H; Papadimitriou A; Gasser T; Stefanis L
    Eur J Neurol; 2014 Jul; 21(7):963-8. PubMed ID: 24313877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Behavioral characterization of A53T mice reveals early and late stage deficits related to Parkinson's disease.
    Paumier KL; Sukoff Rizzo SJ; Berger Z; Chen Y; Gonzales C; Kaftan E; Li L; Lotarski S; Monaghan M; Shen W; Stolyar P; Vasilyev D; Zaleska M; D Hirst W; Dunlop J
    PLoS One; 2013; 8(8):e70274. PubMed ID: 23936403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction between Parkin and
    Madsen DA; Schmidt SI; Blaabjerg M; Meyer M
    Cells; 2021 Jan; 10(2):. PubMed ID: 33572534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Importance of familial Parkinson's disease and parkinsonism to the understanding of nigral degeneration in sporadic Parkinson's disease.
    Hattori N; Shimura H; Kubo S; Wang M; Shimizu N; Tanaka K; Mizuno Y
    J Neural Transm Suppl; 2000; (60):101-16. PubMed ID: 11205133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parkin depletion delays motor decline dose-dependently without overtly affecting neuropathology in α-synuclein transgenic mice.
    Fournier M; Roux A; Garrigue J; Muriel MP; Blanche P; Lashuel HA; Anderson JP; Barbour R; Huang J; du Montcel ST; Brice A; Corti O
    BMC Neurosci; 2013 Nov; 14():135. PubMed ID: 24192137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of LRRK2, SNCA, Parkin, PINK1, and DJ-1 in Zambian patients with Parkinson's disease.
    Yonova-Doing E; Atadzhanov M; Quadri M; Kelly P; Shawa N; Musonda ST; Simons EJ; Breedveld GJ; Oostra BA; Bonifati V
    Parkinsonism Relat Disord; 2012 Jun; 18(5):567-71. PubMed ID: 22445250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPR-Cas9 Gene Editing Protects from the A53T-SNCA Overexpression-Induced Pathology of Parkinson's Disease
    Yoon HH; Ye S; Lim S; Jo A; Lee H; Hong F; Lee SE; Oh SJ; Kim NR; Kim K; Kim BJ; Kim H; Lee CJ; Nam MH; Hur JW; Jeon SR
    CRISPR J; 2022 Feb; 5(1):95-108. PubMed ID: 35191750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death.
    Martin LJ; Pan Y; Price AC; Sterling W; Copeland NG; Jenkins NA; Price DL; Lee MK
    J Neurosci; 2006 Jan; 26(1):41-50. PubMed ID: 16399671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.